GSK’s Zejula reduces risk of progression and death in mesothelioma study
GSK’s Zejula (niraparib) has reduced the risk of death or progression by 27% in patients with mesothelioma in an investigator-led…
All articles by Abigail Beaney
Abigail Beaney
Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including neurodegenerative, infectious and metabolic diseases. Abigail holds a first-class BA (Hons) degree in Journalism from the University of Central Lancashire in the United Kingdom. She has also obtained the National Qualification in Journalism through the UK's media industry body, the National Council for the Training of Journalists. Contact Abigail
-
-
AstraZeneca’s Truqap fails in another Phase III trial
AstraZeneca has discontinued a Phase III trial of Truqap (capivasertib) after a review concluded that the study was unlikely to…
-
Eli Lilly’s shares up as oral GLP-1RA scores in first Phase III trial
Eli Lilly’s Phase III trial with its oral weight loss pill, orforglipron, has met its primary endpoint, reducing A1C levels…
-
Podcast: What’s next for pharma tariffs?
The US government has signalled a major shift in its trade policies in recent weeks, with several announcements detailing plans…
-
BMS’ Camzyos flops in Phase III non-obstructive hypertrophic cardiomyopathy trial
Bristol Myers Squibb’s (BMS) Phase III trial investigating Camzyos (mavacamten) in patients with non-obstructive hypertrophic cardiomyopathy (nHCM) has failed to…
-
Pfizer drops obesity pill development after liver injury report
Pfizer has terminated the development of its oral obesity candidate danuglipron after a patient on a clinical trial with the…
-
UK Government to invest $764m into new health data service
The UK Government has announced a £600m ($764m) funding pot to create a new Health Data Research Service, reducing red…
-
Rhythm seeks market expansion for Imcivree following Phase III victory
Rhythm Pharmaceuticals is pursuing approval for its rare obesity disorder drug Imcivree in acquired hypothalamic obesity after it showed a…
-
Cassava ends simufilam Alzheimer’s programme after second Phase III failure
Cassava Sciences has officially stopped the development of its investigational drug simufilam in Alzheimer’s disease after it failed to show…
-
Rising Sirturo resistance highlights urgent need for new TB therapies
There have been widespread reports that more effort and funding is needed to combat the TB crisis. As more cases…